Intellia’s NTLA-2002 Receives the US FDA’s ODD for the Treatment of Hereditary Angioedema
- The P-I/II clinical trial evaluates the safety, tolerability, PK & PD of NTLA-2002 in patients with Type I//II HAE. The P-I/II trial also measures the plasma levels of the KLKB1 gene along with the patient’s activity determined by the HAE attack rate measures
- Intellia is currently evaluating NTLA-2002 in the P-I portion of the study which identifies the dose levels of NTLA-2002 to be evaluated in the PBO-controlled P-II portion of the study
- NTLA-2002 is an in vivo CRISPR/Cas9 genome editing designed to prevent angioedema attacks in patients with HAE as it inactivates the KLKB1 gene which encodes the kallikrein precursor protein for prekallikrein
Ref: Globenewswire| Image: Intellia
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.